» Articles » PMID: 20558733

RHAMM Promotes Interphase Microtubule Instability and Mitotic Spindle Integrity Through MEK1/ERK1/2 Activity

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2010 Jun 19
PMID 20558733
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

An oncogenic form of RHAMM (receptor for hyaluronan-mediated motility, mouse, amino acids 163-794 termed RHAMM(Delta163)) is a cell surface hyaluronan receptor and mitotic spindle protein that is highly expressed in aggressive human cancers. Its regulation of mitotic spindle integrity is thought to contribute to tumor progression, but the molecular mechanisms underlying this function have not previously been defined. Here, we report that intracellular RHAMM(Delta163) modifies the stability of interphase and mitotic spindle microtubules through ERK1/2 activity. RHAMM(-/-) mouse embryonic fibroblasts exhibit strongly acetylated interphase microtubules, multi-pole mitotic spindles, aberrant chromosome segregation, and inappropriate cytokinesis during mitosis. These defects are rescued by either expression of RHAMM or mutant active MEK1. Mutational analyses show that RHAMM(Delta163) binds to alpha- and beta-tubulin protein via a carboxyl-terminal leucine zipper, but in vitro analyses indicate this interaction does not directly contribute to tubulin polymerization/stability. Co-immunoprecipitation and pulldown assays reveal complexes of RHAMM(Delta163), ERK1/2-MEK1, and alpha- and beta-tubulin and demonstrate direct binding of RHAMM(Delta163) to ERK1 via a D-site motif. In vitro kinase analyses, expression of mutant RHAMM(Delta163) defective in ERK1 binding in mouse embryonic fibroblasts, and blocking MEK1 activity collectively confirm that the effect of RHAMM(Delta163) on interphase and mitotic spindle microtubules is mediated by ERK1/2 activity. Our results suggest a model wherein intracellular RHAMM(Delta163) functions as an adaptor protein to control microtubule polymerization during interphase and mitosis as a result of localizing ERK1/2-MEK1 complexes to their tubulin-associated substrates.

Citing Articles

Biomimetic Hyaluronan Binding Biomaterials to Capture the Complex Regulation of Hyaluronan in Tissue Development and Function.

Huffer A, Mao M, Ballard K, Ozdemir T Biomimetics (Basel). 2024; 9(8).

PMID: 39194478 PMC: 11351607. DOI: 10.3390/biomimetics9080499.


The non-mitotic role of HMMR in regulating the localization of TPX2 and the dynamics of microtubules in neurons.

Chen Y, Tseng S, Chen P, Hwang E Elife. 2024; 13.

PMID: 38904660 PMC: 11192530. DOI: 10.7554/eLife.94547.


Exploring HMMR as a therapeutic frontier in breast cancer treatment, its interaction with various cell cycle genes, and targeting its overexpression through specific inhibitors.

Shabir A, Qayoom H, Haq B, Abo Mansoor A, Abdelrahim A, Ahmad I Front Pharmacol. 2024; 15:1361424.

PMID: 38576486 PMC: 10991682. DOI: 10.3389/fphar.2024.1361424.


Glioma Stem Cells Are Sensitized to BCL-2 Family Inhibition by Compromising Histone Deacetylases.

Merati A, Kotian S, Acton A, Placzek W, Smithberger E, Shelton A Int J Mol Sci. 2023; 24(18).

PMID: 37761989 PMC: 10530722. DOI: 10.3390/ijms241813688.


Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.

Hinneh J, Gillis J, Mah C, Irani S, Shrestha R, Ryan N Br J Cancer. 2023; 129(8):1350-1361.

PMID: 37673961 PMC: 10575850. DOI: 10.1038/s41416-023-02406-8.


References
1.
Harrison R, Turley E . Active erk regulates microtubule stability in H-ras-transformed cells. Neoplasia. 2001; 3(5):385-94. PMC: 1506201. DOI: 10.1038/sj.neo.7900180. View

2.
Perez E . Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009; 8(8):2086-95. DOI: 10.1158/1535-7163.MCT-09-0366. View

3.
Ramos J . The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol. 2008; 40(12):2707-19. DOI: 10.1016/j.biocel.2008.04.009. View

4.
Schmitt M, Schmitt A, Rojewski M, Chen J, Giannopoulos K, Fei F . RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood. 2007; 111(3):1357-65. DOI: 10.1182/blood-2007-07-099366. View

5.
Lynn B, Li X, Cattini P, Turley E, Nagy J . Identification of sequence, protein isoforms, and distribution of the hyaluronan-binding protein RHAMM in adult and developing rat brain. J Comp Neurol. 2001; 439(3):315-30. DOI: 10.1002/cne.1353. View